News News & Publications Multimeric IgM antibodies targeting DR5 are potent and rapid inducers of tumor cell apoptosis and cell death in vitro and in vivo March, 2019 Read More... IGM Biosciences Appoints M. Kathleen Behrens, Ph.D., to Board of Directors January, 2019 Read More... IGM Biosciences Appoints Misbah Tahir as Chief Financial Officer January, 2019 Read More... IGM Biosciences Appoints Wayne Godfrey, M.D., as Vice President, Clinical Development November, 2018 Read More... Agonistic IgM Antibodies Targeting Immunostimulatory TNFRSF Members GITR and OX40 Enhance Immune Responses beyond that of IgGs November, 2018 Read More... IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors August, 2018 Read More... IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer; Names William Strohl, Ph.D., to Board of Directors August, 2018 Read More... Multimeric Anti-DR5 IgM antibody displays potent cytotoxicity in vitro and promotes tumor regression in vivo April, 2017 Read More... High Avidity Anti-CD20 IgM Antibody for Enhanced Complement-Dependent Cell Killing of Low CD20 Expressing Tumor Cells April, 2016 Read More... IGM-55.5, a novel monoclonal human recombinant IgM antibody with potent activity against B cell leukemia and lymphoma April, 2014 Read More... « Previous 1 2
